Ascentage Pharma Group International American Depository Shares When Issued
N/A
- Market Cap N/A
- Current Price N/A
- High / Low N/A
- Stock P/E N/A
- Book Value N/A
- EPS N/A
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE N/A %
- 52 Week High 22.43
- 52 Week Low 18.18
About
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Analyst Target Price
N/A
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AAPGV
2026-01-17 21:28:59
Ascentage Pharma presented its global innovation strategy at the 44th Annual J.P. Morgan Healthcare Conference, highlighting strong growth driven by its two commercialized hematology products, Olverembatinib and Lisaftoclax. The company also announced IND clearance from the U.S. FDA for its next-generation BTK protein degrader, APG-3288, marking an expansion of its global innovative pipeline. Ascentage Pharma emphasized rapid progress in multiple global registrational Phase III trials and outlined key milestones for 2026, including clinical development advancements and commercial expansion in China.
2025-10-27 05:02:33
Ascentage Pharma plans to raise $149 million through a US IPO by offering 7.3 million American Depositary Shares at $20.34 each, valuing the company at $1.8 billion. This follows a previous option agreement with Takeda worth up to $1.3 billion for their lead drug olverembatinib. The Hong Kong-listed firm saw its shares rise 13.7% following the announcement.
2025-10-27 05:02:33
Ascentage Pharma Group Corp. Ltd. has confidentially filed for an IPO with the U.S. SEC, seeking a dual listing on both U.S. and Hong Kong stock exchanges. This news follows a recent $75 million equity investment from Takeda Pharmaceutical Co. Ltd., where Takeda purchased approximately 24.3 million shares at HK$24.09 (US$3.08) per share.
2025-06-02 23:27:18
Ascentage Pharma presented positive Phase Ib/II clinical data at ASCO 2025 for its novel Bcl-2 inhibitor, lisaftoclax (APG-2575), combined with azacitidine, demonstrating promising antitumor activity and a manageable safety profile in patients with treatment-naïve or relapsed/refractory myeloid malignancies. Notably, the study revealed lisaftoclax's ability to overcome venetoclax resistance, the first such report for a Bcl-2 inhibitor, with a 31.8% overall response rate in venetoclax-refractory patients. This drug is currently under Priority Review in China for R/R CLL/SLL and is being evaluated in four global Phase III trials, marking a significant step towards addressing unmet medical needs in blood cancers.
2025-03-10 10:52:34
This article provides a detailed overview of Ascentage Pharma Group International (NASDAQ: AAPG) stock, including its current price movements, key financial stats like market capitalization and revenue, and upcoming earnings information. It also offers company details, related stock suggestions, and analyses like technical indicators, analyst ratings, and seasonal trends to help investors understand the company's market performance.
